Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Phosphodiesterase (1, 3 & 5) inhibitors attenuate diclofenac-induced acute kidney toxicity in rats.

Tytuł:
Phosphodiesterase (1, 3 & 5) inhibitors attenuate diclofenac-induced acute kidney toxicity in rats.
Autorzy:
Wadie W; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Electronic address: .
Abdel-Razek NS; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Salem HA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Źródło:
Life sciences [Life Sci] 2021 Jul 15; Vol. 277, pp. 119506. Date of Electronic Publication: 2021 Apr 15.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: <2008->: Amsterdam : Elsevier
Original Publication: Oxford; Elmsford, N. Y. [etc.] Pergamon Press.
MeSH Terms:
Acute Kidney Injury/*metabolism
Phosphodiesterase Inhibitors/*pharmacology
Acute Kidney Injury/drug therapy ; Acute Kidney Injury/pathology ; Animals ; Blood Urea Nitrogen ; Cilostazol/pharmacology ; Creatinine/metabolism ; Diclofenac/adverse effects ; Diclofenac/pharmacology ; Kidney/pathology ; Male ; NF-kappa B/metabolism ; Pentoxifylline/pharmacology ; Phosphodiesterase Inhibitors/metabolism ; Phosphoric Diester Hydrolases/metabolism ; Rats ; Rats, Wistar ; Sildenafil Citrate/pharmacology ; Toll-Like Receptor 4/metabolism ; Tumor Necrosis Factor-alpha/metabolism ; Vinca Alkaloids/pharmacology
Contributed Indexing:
Keywords: Cilostazol; Diclofenac; Pentoxifylline; Renal failure; Sildenafil; Vinpocetine
Substance Nomenclature:
0 (NF-kappa B)
0 (Phosphodiesterase Inhibitors)
0 (Toll-Like Receptor 4)
0 (Tumor Necrosis Factor-alpha)
0 (Vinca Alkaloids)
144O8QL0L1 (Diclofenac)
543512OBTC (vinpocetine)
AYI8EX34EU (Creatinine)
BW9B0ZE037 (Sildenafil Citrate)
EC 3.1.4.- (Phosphoric Diester Hydrolases)
N7Z035406B (Cilostazol)
SD6QCT3TSU (Pentoxifylline)
Entry Date(s):
Date Created: 20210418 Date Completed: 20210622 Latest Revision: 20210622
Update Code:
20240104
DOI:
10.1016/j.lfs.2021.119506
PMID:
33865881
Czasopismo naukowe
Diclofenac, one of the most commonly used non-steroidal anti-inflammatory drugs, leads to severe adverse effects on the kidneys. The aim of the present study was to investigate the potential pretreatment effect of phosphodiesterase (1, 3 & 5) inhibitors on diclofenac-induced acute renal failure in rats. Rats orally received pentoxifylline (100 mg/kg), vinpocetine (20 mg/kg), cilostazol (50 mg/kg), or sildenafil (5 mg/kg) once per day for 6 consecutive days. Diclofenac (15 mg/kg) was injected on day-4, -5 and -6 in all groups except normal control group. The used phosphodiesterase inhibitors significantly reduced the diclofenac-induced elevation in the serum levels of blood urea nitrogen, creatinine and cystatin C. Moreover, the renal tissue contents of tumor necrosis factor (TNF)-α, nuclear factor (NF)-κB as well as the protein expression of toll-like receptor (TLR) 4 and high mobility group box (HMGB) 1 were markedly reduced by the used phosphodiesterase inhibitors, as compared to the diclofenac control. This was reflected on the marked improvement in histopathological changes induced by diclofenac. Sildenafil showed the best protection regarding TNF-α and NF-κB, while cilostazol showed the best results regarding TLR4, HMGB1 and histopathological examination. This study revealed the good protective effect of these phosphodiesterase inhibitors against diclofenac-induced acute renal failure.
(Copyright © 2021. Published by Elsevier Inc.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies